Gilead Sciences Announces Late-Breaking Clinical Data And Real-World Evidence To Be Presented At HIV Glasgow As Co Extends Leadership Efforts Toward Ending The Epidemic
Gilead Sciences Announces Late-Breaking Clinical Data And Real-World Evidence To Be Presented At HIV Glasgow As Co Extends Leadership Efforts Toward Ending The Epidemic
Gilead Sciences, Inc. (NASDAQ:GILD) today announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November 10-13. The results from more than 40 studies across HIV treatment and prevention include late-breaking data and seven oral presentations. These findings reflect a robust portfolio and future-looking pipeline focused on person-centered drug development strategies to address unmet needs in HIV and help end the epidemic.– Full Results From PURPOSE 2 Study Exploring Lenacapavir as a Potential Twice-Yearly HIV Prevention Option Among a Broad and Geographically Diverse Range of Cisgender Men and Gender-Diverse People –
— PURPOSE 2研究的完整结果，该研究探讨了来那卡韦作为广泛且地域多样化的顺性别男性和性别多样化人群中每年两次的潜在艾滋病毒预防选择—
– Four-Year Outcomes From Real-World BICSTaR Study Further Demonstrate the Consistent Efficacy and Safety Profile of Biktarvy, Providing Insights for HIV Clinical Care –
— 来自真实世界的BicStar研究的四年结果进一步证明了Biktarvy的一致疗效和安全性，为HIV临床护理提供了见解—
– Late-Breaking Oral Presentation From Phase 2 Study Evaluating an Investigational Once-Weekly Oral Combination Treatment Regimen of Islatravir/Lenacapavir –
— 第二阶段研究的最新口头陈述，该研究评估了正在研究的每周一次的艾拉曲韦/来那卡韦口服联合治疗方案 —
Gilead Sciences, Inc. (NASDAQ:GILD) today announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November 10-13. The results from more than 40 studies across HIV treatment and prevention include late-breaking data and seven oral presentations. These findings reflect a robust portfolio and future-looking pipeline focused on person-centered drug development strategies to address unmet needs in HIV and help end the epidemic.
吉利德科学公司（纳斯达克股票代码：GILD）今天宣布，即将在11月10日至13日举行的艾滋病毒感染药物治疗国际大会（2024年格拉斯哥艾滋病毒）上介绍艾滋病毒研究成果。40多项有关艾滋病毒治疗和预防的研究结果包括最新数据和七次口头陈述。这些发现反映了强大的产品组合和面向未来的产品线，这些产品线侧重于以人为本的药物研发战略，以满足未满足的艾滋病毒需求并帮助终结疫情。
